PD1-Vaxx Immunotherapy for Non-Small Cell Lung Cancer
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial tests IMU-201 (PD1-Vaxx), a new treatment for adults with Non-Small Cell Lung Cancer. It aims to help the immune system create antibodies to fight cancer cells more effectively and safely than current treatments.
Are You a Good Fit for This Trial?
Adults over 18 with advanced non-small cell lung cancer (NSCLC) who have either not been treated or have progressed after treatment with PD-1/PD-L1 inhibitors. They should be in relatively good health, with a life expectancy of at least 12 weeks and able to perform daily activities with little assistance (Zubrod/ECOG score 0-1). Patients must not have received certain treatments recently, have active infections requiring IV antibiotics, known HIV/Hepatitis B/C infection, uncontrolled other cancers or brain metastases needing steroids.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Dose Escalation
Phase 1 monotherapy dose-escalation of IMU-201 (PD1-Vaxx) to establish the optimal monotherapy biological dose (mBOD).
Dose Expansion
Expansion of the dose cohort to enroll additional patients at the mBOD dose level.
Combination Dose Escalation
Phase 1b combination dose-escalation of IMU-201 (PD1-Vaxx) with atezolizumab and with or without chemotherapy to establish the optimal combotherapy biological dose (cBOD).
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- IMU-201 (PD1-Vaxx)
Find a Clinic Near You
Who Is Running the Clinical Trial?
Imugene Limited
Lead Sponsor